1-2 of 2
Dan Gombos, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MD MSc, Michelle Velasquez, RN, Mary Kelly, Jing Ning, PhD, Graciela M. Nogueras González, MPH, Sherry A. Pierce, BSN, BA, Dan Gombos, MD, Zeev E. Estrov, MD, Steven M. Kornblau, MD, Weiguo Zhang, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1441.
https://doi.org/10.1182/blood-2018-99-118028
Published: 2018
Journal Articles

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval Daver, MD, Rita Assi, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Jing Ning, PhD, Graciela Nogueras González, Sherry Pierce, BSN, BA, Mary Kelly, Weiguo Zhang, MD PhD, Dan Gombos, MD, Steven Kornblau, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1344.
https://doi.org/10.1182/blood.V130.Suppl_1.1344.1344
Published: 2017